Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;129(10):1216-1218.
doi: 10.1016/j.ophtha.2022.06.008. Epub 2022 Jun 15.

Retinopathy of Prematurity Treatment Trends from 2003 to 2020 in the United States

Suleman I Khan  1 , Won Yeol Ryu  2 , Edward H Wood  1 , Darius M Moshfeghi  1 , Jennifer Krupa Shah  1 , Scott R Lambert  3
Affiliations

Retinopathy of Prematurity Treatment Trends from 2003 to 2020 in the United States

Suleman I Khan et al. Ophthalmology. 2022 Oct.

Abstract

We used population-based data obtained from Optum’s Clinformatics® Data Mart Database to characterize recent trends in retinopathy of prematurity (ROP) treatments and outcomes in the United States. Laser photocoagulation was utilized more frequently every year compared to anti-VEGF.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflicting relationship exists for any author.

Figures

Figure 1:
Figure 1:
Usage of laser photocoagulation and Anti-VEGF treatments between 2003-2020 in the Optum Clinformatics® Data Mart Database. Laser therapy continues to be most frequently used, but Anti-VEGF usage had an uptick beginning in 2011. Although 43 patients were diagnosed with ROP in our dataset between January 1, 2018-June 30, 2020, none were treated with solo- laser or Anti-VEGF. The exact counts for Anti-VEGF in 2009-2011 and the combination therapy group are masked due to N <15.
See this image and copyright information in PMC

References

    1. Ludwig CA, Chen TA, Hernandez-Boussard T, Moshfeghi AA, Moshfeghi DM. The Epidemiology of Retinopathy of Prematurity in the United States. Ophthalmic Surg Lasers Imaging Retina. 2017;48:553–62. - PubMed
    1. Prakalapakorn SG, Greenberg L, Edwards EM, Ehret DEY. Trends in Retinopathy of Prematurity Screening and Treatment: 2008-2018. Pediatrics. 2021;147:1–8. - PubMed
    1. Zhang MH, Blair MP, Ham SA, Rodriguez SH. Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database. Ophthalmic Surg Lasers Imaging Retina. 2020;51:486–93. - PubMed
    1. Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology .2014;121:2212–9. - PubMed
    1. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–48; discussion 48-50. - PMC - PubMed

Publication types